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Abstract
Background: Neuroferritinopathy (NF) is a rare autosomal dominant disease caused by mutations in the ferritin light chain 1 (FTL1) gene leading to abnormal
excessive iron accumulation in the brain, predominantly in the basal ganglia.
Methods: A literature search was performed on Pubmed, for English-language articles, utilizing the terms iron metabolism, neurodegeneration with brain iron
accumulation, and NF. The relevant articles were reviewed with a focus on the pathophysiology, clinical presentation, differential diagnoses, and management of NF.
Results: There have been nine reported mutations worldwide in the FTL1 gene in 90 patients, the most common mutation being 460InsA. Chorea and dystonia are the
most common presenting symptoms in NF. There are specific features, which appear to depend upon the genetic mutation. We discuss the occurrence of specific mutations
in various regions along with their associated presenting phenomenology. We have compared and contrasted the commonly occurring syndromes in the differential
diagnosis of NF to guide the clinician.
Discussion: NF must be considered in patients presenting clinically as a progressive movement disorder with variable phenotype and imaging evidence of iron deposition
within the brain, decreased serum ferritin, and negative genetic testing for other more common movement disorders such as Huntington’s disease. In the absence of a
disease-specific treatment, symptomatic drug therapy for specific movement disorders may be used, although with variable success.
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Introduction
Neuroferritinopathy (NF) is an autosomal dominant, late-onset basal
ganglia disorder resulting from mutations in the gene for ferritin light
chain 1 (FTL1) on chromosome 19q13.1,2 The pathogenic mutations in
the FTL1 gene cause pathological iron deposition and ferritin
inclusions in various brain regions, respecting the pattern observed
in normal aging.1 NF belongs to the group of disorders collectively
known as neurodegeneration with brain iron accumulation (NBIA).
The NBIAs present as a progressive extrapyramidal syndrome with
abnormally increased iron deposition in the brain, particularly
affecting the basal ganglia.3 Pantothenate kinase-associated neurode-
generation (PKAN) and PLA2G6-associated neurodegeneration are the
two most common disorders in this group. NF is one of only two
disorders in this expanding group of NBIAs caused by a mutation
in genes directly involved in iron metabolism; the other being
aceruloplasminemia.4 It is the only autosomal dominant NBIA
disorder, and patients present late in adulthood with combinations
of movement disorders.2 To date, 90 cases of NF have been identified
with nine causative mutations. On the basis of recent advances in our
knowledge about NF, we review the various aspects of NF, namely the
pathophysiology, genetics, clinical manifestations, differential diagno-
sis, treatment options, and prognosis.
Pathophysiology
The brain requires iron for many of its essential activities including
transport of oxygen, energy generation, development of oligodendrocytes,
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myelin synthesis, production of neurotransmitters (dopamine, serotonin,
and norepinephrine), and metabolism of nitric oxide.5,6 The brain
contains about 30–40 mg of iron, which forms less than 1% of the total
iron in our body.7 Disturbances in the homeostatic mechanisms of iron
metabolism cause oxidative stress and cellular damage.6 Iron content in
the brain increases with age, but it is still unclear whether its accumulation
in neurodegenerative disorders is a primary or a secondary phenom-
enon.3,4 The distribution of iron in the brain is not homogeneous. The
basal ganglia (caudate, putamen, and globus pallidus) have the highest
iron concentrations, while the cortex, brainstem, and cerebellum have
relatively lower concentrations.6,8 Iron is mainly stored intracellularly in
the ferritin complex; however, in the substantia nigra and locus ceruleus,
neuromelanin is the major iron storage molecule.4
To get into the brain, iron needs to cross the blood–brain barrier
and blood–cerebrospinal fluid (CSF) barrier. Iron is transported by
transferrin (Tf), which binds to transferrin receptors (TfR) on the cell
surface.9 Of the two TfRs (TfR1 and TfR2), TfR1 plays the primary
role in iron transfer.9 The Tf–TfR system is mainly responsible for
exporting iron from the vascular lumen into the vascular endothelial
cells. Iron is exported out of the basolateral membrane through some
unknown transporters, which may involve ferroportin.6 Extracellular
iron then enters the astrocytes as low molecular weight complexes (e.g.
citrate, adenosine triphosphate, ascorbate) or it may enter the neurons
via the Tf–TfR pathways (Figure 1).9 Iron can be stored as ferritin in
astrocytes and released through ferroportin and ceruloplasmin, the
ferroxidase that oxidizes ferrous iron.10 Astrocytes are ideally positioned
to take up iron from the circulation and disperse it among other central
nervous system cells.10
Ferritin, the major iron storage protein, has a spherical shell with an
internal cavity that can store 4,500 iron atoms.11 It is composed of two
subunit types, heavy (H) and light (L), which are encoded by genes on
chromosomes 11 and 19, respectively.7,11 Both H and L chains are
essential as the heteropolymers assimilate iron more effectively than
homopolymers.12 In NF, the mutations produce a lengthening of the C
terminus of the L chain that impairs its normal interaction with the
heavy chain, thereby impairing the iron-binding capacity of ferri-
tin.11,13 This results in accumulation of ferrous or free iron (Fe2+),
which causes damage by producing free radicals, and a compensatory
upregulation of ferritin production (Figure 1).1,13 Oxidative stress leads
to neurodegeneration.12 Mitochondrial dysfunction may also con-
tribute to the cellular dysfunction in NF probably by affecting neuronal
intramitochondrial iron handling.2,14–16
Curtis et al. were the first group to report NF cases in a large north
England family from the Cumbria region who had dominantly
inherited, adult-onset basal ganglia disease.1 They found a mutation of
an adenine insertion at position 460–461 in exon 4 of the FTL1 gene,
which caused a frameshift and led to alterations at the C terminus of
the gene product. The number of reported cases and mutations in NF
are gradually increasing, thus underlining the fact that NF is neither
purely confined to the population of north England nor confined to a
common founder, as was once thought (Table 1).2,13,14,16–22 Most
FTL1 mutations are located on exon 4, commonly resulting in a
Figure 1. Cellular Iron Metabolism in the Central Nervous System and Abnormalities in Neuroferritinopathy. Adapted from Dringen et al.10,
Schneider et al.3 and Levi and Finazzi.12 Transferrin (Tf)-bound ferric iron (Fe3+) enters the cell (astrocyte) through adenosine triphosphate (ATP)-dependent trans-
ferrin receptor (TfR)-mediated endocytosis, and ferrous iron (Fe2+) via a divalent metal transporter 1 (DMT1). STEAP 3, a ferrireductase, converts Fe3+ to Fe2+.
Excess iron is stored in ferritin as Fe3+. Fe2+ is exported out via ferroportin (FP), where it is oxidized by ceruloplasmin (CP) to Fe3+ and is available for other central
nervous system cells, i.e., neurons and oligodendrocytes. The solid arrows show the normal iron metabolic pathways and the dotted arrows depict the pathogenic
mechanisms in neuroferritinopathy (NF). The FTL1 gene mutation reduces the effectiveness of iron incorporation in ferritin and causes faster ferritin degradation. In
turn, the increase in cytosolic iron induces upregulation of the abnormal ferritin. This stimulates production of reactive oxygen species (ROS) and oxidative damage
leading to proteasome impairment and cell death. H, Heavy Subunit; L, Light Subunit.
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frameshift, suggesting that this part of the gene is particularly
vulnerable to mutation.11
Clinical features
NF usually presents in the second to fifth decade of life with the mean
age of onset being around 40 years.1,2,13,15,19 Those with mutations
other than 460InsA appear to have an earlier age of onset (Table 1).
The gender of the patients does not affect the age of disease onset or
clinical phenotype. Although no predilection was seen for any gender in
the largest series,2 some series report male predominance.19,27,31 It was
suggested that females might be less vulnerable to abnormal iron
deposition owing to menstruation,19 which may explain an asympto-
matic 40-year-old female carrier in one of the reports.17 The disorder is
thought to be fully penetrant by the age of 60.2,33 Clinical presentation
does not differ with the age of onset. A strong family history is reported
in most of the series.1,2,13 The disease progresses gradually, first
involving basal ganglionic and/or cerebellar functions, and spreads to
involve cortical functions in the late stages.13 The clinical manifestations
vary among NF patients, which may be related to the variability in
length of the mutant polypeptide and the resulting dominant negative
effect of the modified last alpha-helix domain.14 However, there is no
known correlation between the length of the mutant polypeptide and the
age of onset. Environmental factors like dietary iron intake and other
genes influencing iron metabolism may affect the clinical picture.21
Motor symptoms
NF may present with varied movement disorders. Three of the 90
cases reported to date were asymptomatic,2,17 and clinical data were not
available for four additional reported NF patients.13,31 On analyzing all
the symptomatic reported cases of NF (n583; Figure 2), we found
chorea (39.7%; n533) and dystonia (38.5%; n532) to be the commonest
presenting features; however, these were not specific for any particular
FTL1 mutation or a geographical region. Parkinsonism (6%; n55) and
tics (1.2%; n51) as initial presentation were seen in only those patients
with 460InsA mutations. Tremor (7.2%; n56) at the disease onset was
seen in patients of French ancestry with 498InsTC, and in Japanese
patients with 469_484dup16nt. The 469_484dup16nt mutation is also
seen in Italy, presenting with similar clinical features. Cerebellar ataxia
(4.8%; n54) as the presenting movement disorder was common in patients
of French ancestry with 498InsTC mutations. Those with 460InsA
mutations are unlikely to present with tremor and cerebellar ataxia.
The abnormal movements may remain asymmetric throughout the
disease course in almost two-thirds of patients.2 Irrespective of the initial
presentation, most patients develop dystonia (83%), predominantly in the
lower limbs, and/or chorea (70%).2 Cerebellar symptoms such as
dysmetria, ataxia, and palatal tremor are reported in patients with NF
and may appear at any stage of the disease.2,13,14,16,17,20,22,23,26,31
Although unsteady gait and repeated falls may appear early in NF,14,27
the majority of patients remain mobile even after 20 years of disease
onset.2 Patients with dystonic presentation have the most severe physical
disability.2 Dysarthria and dysphagia have been reported in many
patients.2,16,19,20,22,26,27,30,34 Oromandibular dyskinesia (65%), impairment
of voice and speech (dysarthrophonia) with action-specific facial dystonia
(63%) are commonly seen,2,13,20,22,24 and felt by one group to be specific to
NF.24 Facial tics may be seen.26 Although changes in handwriting are
expected to occur in most of the patients, micrographia has been
specifically reported.16 Rarely, patients may present with ballistic move-
ments,2 alien limb phenomenon,2 blepharospasm,2,24,30 or writer’s cramp.2
Pyramidal signs including spasticity,1 brisk deep tendon reflexes,32 and
Babinski signs13,16,22 have been reported in patients with NF. Hypotonia
may be seen.19,22,32 Although extraocular movements are usually well
preserved, some patients may develop saccadic pursuit,2,16,23 slow
saccades,16,22,23 and apraxia of eyelid opening.16,23 Limitation of vertical
eye movements20 and horizontal oculomotor dysmetria21 are reported.
Cognitive decline and psychiatric symptoms
The onset of cognitive impairment may vary from the first decade to
more than three decades after the onset of motor symptoms.2,13–
15,19,21,25,32,34 One study reported neurocognitive features presenting
within 5 years of onset of the motor manifestations.34 Mild deficits in
verbal fluency may be seen early.2 Features suggestive of frontal and
subcortical cognitive impairment like disinhibition, reduced verbal
fluency, executive dysfunction (working memory), and attention
difficulties predominate.2,13,15,21,25 Rarely, patients may present with
psychiatric symptoms (2.4%; n52) (Figure 2). Japanese patients
presented more commonly with psychiatric symptoms and cognitive
decline. Anxiety,13 paranoid delusions,35 acute psychosis,17 or depres-
sion16,19,20 have been reported to occur anytime in the course of NF.
Other features
Sleep disturbances, including insomnia,13 sleep apnea,35 and central
sleep apnea with restrictive respiratory insufficiency causing excessive
Figure 2. Initial Presentations of Neuroferritinopathy Patients with
Respective Mutations in Reported Symptomatic Cases. Chorea (39.7%)
and dystonia (38.5%) are the most common initial presentations, followed by
tremor (7.2%), parkinsonism (6%), cerebellar ataxia (4.8%), psychiatric symptoms
(2.4%) and tics (1.2%). The associated mutations are listed alongside the
symptoms.
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daytime sleepiness,20 have been reported. Other features may include
areflexia and a positive Romberg test;16 features of dyautonomia such
as othostatic hypotension,20,22 constipation,20 urinary incontinence20
and impotence;16 fatigue14 and pseudobulbar effect.16,19,22 Chronic
headache may also be a presenting symptom.22 Sensory abnormalities
in the large fiber sensations (vibration and proprioception) and positive
frontal release signs have been reported.26
Differential diagnoses
The varied clinical presentations of NF make for a long list of
differential diagnoses. Common differential diagnoses are listed in
Table 2. Others may include Niemann–Pick type C (NPC) and
mitochondrial disease.2 Marked supranuclear gaze impairment favors
a diagnosis of NPC.2 Although there are overlaps in the clinical,
radiological, and muscle biopsy findings between NF and mitochon-
drial disorders, positive genetic testing for FTL1 mutation confirms the
diagnosis of NF.2 Additional brain immunocytochemical abnormalities
indicate a secondary defect of the respiratory chain in NF.16 Early in
the course of NF, patients may present with features of writer’s cramp,
blepharospasm, or restless leg syndrome.2 A family history of NF,
decreased serum ferritin, and magnetic resonance imaging (MRI)
brain suggestive of abnormal iron storage in the basal ganglia may
point to the diagnosis of NF in such patients.2
Investigations
Laboratory investigations
Complete blood count, renal function tests, copper studies (serum
ceruloplasmin and copper, and 24-hour urinary copper), and serum
creatine kinase are typically normal in NF.1,2,15,23,35 Liver function tests
may be abnormal.13 Serum ferritin levels may be decreased1,2,14,17,20,21,32
or in the normal range.16,19,22,23,35 Although decreased serum ferritin was
not uniformly seen in all the cases, a low serum ferritin in the setting of an
unknown movement disorder with autosomal dominant family history
suggests the diagnosis of NF. In the largest series of patients, the serum
ferritin was decreased in 82% of males and all postmenopausal females,
but only in 23% of premenopausal females.2 This may be explained
because of the loss of iron owing to menstruation in premenopausal
females.2,19 Decreased CSF ferritin was reported by Nishida et al.22 Nerve
conduction studies are normal.23
Neuroimaging
Key features on brain imaging support the diagnostic consideration
of NF.11 Features of iron deposition precede evidence of atrophy and
necrosis on brain MRI.29,36 Brain MRI may show basal ganglia
cavitation or cystic changes (predominantly in the globus pallidus and
putamen),1,15,16,18,20,21,28,29,36 hyperintensity with surrounding hypoin-
tensity on T2-weighted imaging involving the putamen, pallidum,
thalamus, substantia nigra, and the dentate nucleus,2,18,19,22,23,35
cortical atrophy,13,14,17,23,31 pontine atrophy,13 and cerebellar atro-
phy.13,16,28,31 T2-weighted images showing a hypointense rim with
hyperintense center in the globus pallidus (‘‘eye of the tiger sign’’),
considered pathognomic of PKAN,3 is reported in NF.22,36 This MRI
signature may also be seen in cortico-basal ganglionic degeneration,
multiple system atrophy, progressive supranuclear palsy, and pure
akinesia with gait freezing.22,36 While thalamic iron stores correlate
with the severity of dystonia,29 voxel-based analysis showed correlation
between caudate iron stores and globus pallidus cavitation to the
severity in NF patients.28 Iron deposition in the cortex,28,30,36 on
susceptibility-weighted imaging sequence on MRI, produces a
hypointense fine signal band along the cortical contours and is termed
‘‘pencil-lining.’’30 Patients older than 50 years of age or those with
disease duration of more than 10 years develop more severe basal
ganglia cavitation.29 Rarely, the brain MRI may be normal in the
initial stage of the disease.35 Asymptomatic persons with positive gene
mutation may have abnormal brain MRI.17 MRI brain findings in
some patients with NF may remain asymmetric.16,21,25
Genetic testing
Genetic testing for the FTL1 gene mutation on chromosome
19q13.3 is confirmatory.11 Rarely, the individual may be asympto-
matic despite a confirmed mutation.2,17 Of the nine causative FTL1
mutations reported to date, 460InsA is the most common in patients of
British descent and 498InsTC is common in patients with French
ancestry. The 460InsA mutation has not been found in Japanese
patients.
Neuropathology
Mild cerebral and cerebellar atrophy with basal ganglia cavitation
and numerous iron-positive inclusions especially in the globus pallidus
and putamen are seen on neuropathological examination.1,13,16
Intranuclear and intracytoplasmic ferritin deposition in astrocytes
and oligodendroglia are seen in the caudate nucleus, putamen, globus
pallidus, and in gray and white matter regions.13,16 Ferritin deposits
are also seen in cerebellar granule cells and Purkinje cells.13 The
ferritin deposits may be seen in the parenchymal cells of other organs
like skin fibroblasts, renal tubule cells, and endothelial cells of muscle
capillaries.13 Intranuclear iron and ferritin inclusions are also found in
hepatocytes.16 This points to the fact that the pathology of NF is not
limited to the brain tissue only and some authors suggested that
‘‘hereditary ferritinopathy’’ is a better term than the more restrictive
‘‘neuroferritinopathy.’’4,13,16 Muscle biopsy in a few NF patients
showed evidence of mitochondrial respiratory chain defects.2,14–16
Chinnery et al.2 found a higher percentage of cytochrome c oxidase
negative fibers than expected for age in two out of nine NF patients
who underwent muscle biopsy. Respiratory chain complex assays
reported in eight patients found isolated or combined defects in seven
of them. While isolated defects in complex I2 and complex III14 were
seen in three and one patient respectively, three other patients had a
combined defect involving multiple respiratory chain complexes.2,16 A
generalized deficiency was reported in a sample of post-mortem
cerebellar tissue.16 These respiratory chain defects suggest mitochon-
drial dysfunction in NF.
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Management
At present, there are no established guidelines or specific management
recommendations for patients with NF.27 An individualized symptomatic
approach to treatment is recommended. A number of drugs have been
used for symptomatic management in NF with variable success. Dystonia
either showed some2,21,23,35 or no14,16,19,22 improvement with antic-
holinergics such as trihexyphenidyl. While variable improvement in
chorea, tics, and stereotypy were reported with sulpiride (D2 receptor
blocker) and tetrabenazine (dopamine depleting agent) in some patients,
the latter is associated with complications including sedation, parkinson-
ism, and depression.2,26,27,35 One report showed excellent response of
facial tic/stereotype and chorea with tetrabenazine.26 Parkinsonian
symptoms of NF showed either no2,22,27 or only some initial benefit20,35
with levodopa. Benzodiazepines (diazepam, clonazepam, and lorazepam)
have been shown to improve dystonia in a few patients,2,35 but not in
others.19,22 Antidepressants, like fluoxetine, were helpful in treating
depression.16,19 Muscle relaxants, like baclofen, gave either partial35 or
no2,22 benefit in treating dystonia. Various other drugs that have failed to
improve the movement disorders include risperidone2, haloperidol,13,19,27
tiapride,19 olanzapine,2 amitriptyline,2,16,35 apomorphine,2,35 amanta-
dine,2 dopamine agonists,14 deanol,2 dantrolene,2 paroxetine,2 mirtaza-
pine,2 gabapentin,2 sodium valproate,2,22 and carbamazepine.2,35 One
author reported improvement in the finger dystonia of a patient with
herbal medicine (Shakuyaku-kanzo-to).22 Physiotherapy in addition to
drugs improved dystonia and gait in one patient.22 Speech amplification
may help hypophonia.2
Moderate benefits have been reported with the use of botulinum
toxin for dystonia affecting the neck, orofacial region (including
blepharospasm), and extremities.2,16,21,35 Other symptomatic treat-
ments include non-invasive positive pressure ventilation for sleep
apnea and percutaneous endoscopic gastrostomy feeding for severe
weight loss due to dysphagia.20,27 Dysphagia should be monitored and
managed with swallowing assessment and dietary modification.2
A number of treatments have been used for modulating the brain iron
stores in the hope of reversing the pathology, but none have been reported
to be successful. A low-iron diet did not show benefit after 6 months of its
institution.16 Iron chelation therapy with desferrioxamine (4,000 mg weekly
subcutaneously for up to 14 months)2 and deferiprone (15 mg/kg/day for 6
months) have not been effective.2,14 No improvement was seen with
monthly venesection.2,16,19 Although no benefit has been reported in the
short term with iron-modulating therapies, the long-term response has yet to
be studied.
Although NF progresses gradually but relentlessly in most of the
patients,2,13 patients with a 458dupA mutation show a relatively rapid pro-
gression of parkinsonism, ataxia, and neuropsychiatric symptoms.20 Patients
usually die of aspiration pneumonia.16,19 Other reported causes of death
include community-acquired pneumonia,27 asphyxiation of food,19 and
cardiomyopathy.20 It is not known whether this last cause was related to NF.
Conclusion
NF is a rare autosomal dominant disease with FTL1 mutation
leading to abnormal excessive iron accumulation in the brain
(predominantly in the basal ganglia) and other organ systems. In
people of British descent, the most common mutation is 460InsA. Nine
variant mutations in the FTL1 gene have been reported in various
geographical regions. NF patients with mutations other than 460InsA
appear to have an earlier age of onset. Although NF has heterogeneous
clinical presentations, chorea and dystonia are the most common
presenting symptoms; however, these are not specific to a mutation.
There are however specific features that depend on the genetic mutation
and hence on regional distribution as reviewed in this manuscript.
NF must be considered in patients presenting clinically as a
relentlessly progressive movement disorder with variable phenotype
and imaging evidence of iron deposition within the brain, decreased
serum ferritin, and negative genetic testing for other more common
movement disorders like Huntington’s disease. The FTL1 gene mutation
should be suspected despite the lack of a positive family history, as new
genetic mutations of this gene may occur in any population. Brain MRI
is helpful, even during the pre-symptomatic period in relatives of
affected patients, and unilateral or asymmetric lesions do not exclude the
diagnosis. Although MRI features may overlap with other NBIAs, basal
ganglia cavitation and cortical ‘‘pencil-lining’’ on susceptibility-weighted
imaging favors NF. Standard symptomatic drug treatment for specific
movement disorders may be used with variable success. Chelation
therapies have not been shown to be effective.
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